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There are two types of feline coronaviruses that can be distinguished by serology and sequence
analysis. Type I viruses, which are prevalent in the field but are difficult to isolate and propagate in
cell culture, and type II viruses, which are less prevalent but replicate well in cell culture. An
important determinant of coronavirus infection, in vivo and in cell culture, is the interaction of the
virus surface glycoprotein with a cellular receptor. It is generally accepted that feline
aminopeptidase N can act as a receptor for the attachment and entry of type II strains, and it has
been proposed that the same molecule acts as a receptor for type I viruses. However, the
experimental data are inconclusive. The aim of the studies reported here was to provide evidence
for or against the involvement of feline aminopeptidase N as a receptor for type I feline
coronaviruses. Our approach was to produce retroviral pseudotypes that bear the type I or type
II feline coronavirus surface glycoprotein and to screen a range of feline cell lines for the
expression of a functional receptor for attachment and entry. Our results show that type I feline
coronavirus surface glycoprotein fails to recognize feline aminopeptidase N as a functional
receptor on three continuous feline cell lines. This suggests that feline aminopeptidase N is not a
receptor for type I feline coronaviruses. Our results also indicate that it should be possible to use
retroviral pseudotypes to identify and characterize the cellular receptor for type I feline
coronaviruses.
INTRODUCTION
Coronaviruses are enveloped, plus-stranded RNA viruses
that cause widespread disease in humans and animals. They
tend to infect just one or a few closely related species and in
their natural host exhibit marked tissue tropism. Often, the
respiratory or gut epithelia are specifically targeted, causing
localized infection, but disseminated infections leading to
systemic disease are also seen. Together with toroviruses,
arteriviruses and roniviruses, coronaviruses are members of
the order Nidovirales (Siddell et al., 2005).
Feline coronavirus (FCoV) infection is extremely common
in cats. Natural infections with FCoV are usually transient,
although a significant percentage of infections may become
persistent (Addie & Jarrett, 2001). Most infections are
asymptomatic or result in mild, self-limiting gastrointes-
tinal disease, and in these cases the causative agent is
known as feline enteric coronavirus (FECV). In a small
percentage (,5%) of animals, however, a fatal multi-
systemic, immune-mediated disease occurs and this is
known as feline infectious peritonitis (FIP) (Pedersen,
1995). Virus associated with FIP is referred to as feline
infectious peritonitis virus (FIPV).
There are two types of FCoV that can be distinguished by
serology and sequence analysis. Type I viruses are most
prevalent in the field and account for approximately 80%
of all infections (Addie et al., 2003; Hohdatsu et al., 1992).
Type II viruses are less prevalent and are characterized by
recombination events that result in the replacement of the
FCoV spike (S) glycoprotein gene with the equivalent gene
of canine enteric coronavirus (CCoV) (Herrewegh et al.,
1998). There is no evidence that either type is more
commonly associated with FIP in natural infections
(Benetka et al., 2004). The majority of research on FCoV
to date has concentrated on the investigation of type II
strains, most notably FIPV 79-1146, because they replicate
well in cell culture.
The species specificity of coronaviruses is, to a large extent,
determined by the recognition of a functional receptor
on the surface of the host cell (Kuo et al., 2000).
Coronaviruses use a variety of cellular receptors (Masters, Supplementary tables are available with the online version of this paper.
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receptors are used by different coronaviruses (Li et al.,
2003; Yeager et al., 1992). It is accepted that type II FCoV
strains use feline aminopeptidase N (fAPN) as a receptor
for host attachment and entry (Tresnan et al., 1996).
Consequently, they can be readily propagated in cell lines
such as Crandell feline kidney (CrFK) cells, which express
fAPN on their surface (Miguel et al., 2002). In contrast,
there is conflicting evidence regarding the receptor for the
attachment and entry of type I FCoV. Tresnan et al. (1996)
have reported that the UCD-1 strain of FIPV, which is
a type I virus, also uses fAPN as a receptor, albeit
inefficiently. Their conclusion was based upon the ability
of the UCD-1 strain to infect and express viral antigens in
both hamster and mouse cells (which, normally, cannot be
infected) that had been stably transfected with fAPN
cDNA. In contrast, Hohdatsu et al. (1998) have concluded
that fAPN is not a receptor for type I FCoV. Their
conclusion is based upon the ability of an fAPN-specific
monoclonal antibody (mAb), R-G-4, to block the infection
of Felis catus whole foetus (Fcwf-4) cells with type II
viruses, whereas the same antibody was not able to block
infection with type I viruses.
The aim of the studies reported here was to provide
evidence for or against the involvement of fAPN as a
receptor for type I FCoV. Our approach was to produce
retroviral pseudotypes that bear type I or type II FCoV S
glycoprotein and produce a green fluorescent protein
(GFP) reporter gene signal in transduced cells. We chose
this approach because human coronavirus S glycoproteins
have been successfully pseudotyped onto similar retroviral
vectors and then used to analyse the recognition of cellular
receptors (Hofmann et al., 2006; Simmons et al., 2004;
Temperton et al., 2005). In our case, the pseudotypes were
used to screen a range of feline cell lines for the expression
of a functional receptor for attachment and entry. Our
results clearly show that type I FCoV S glycoprotein
fails to recognize fAPN as a functional receptor on three
continuous feline cell lines. This suggests fAPN is not the
receptor for type I FCoV. Our results also demonstrate that
these retroviral pseudotypes can be used to screen for cells
that are permissive for attachment and entry with FCoV,
and we conclude that they can be used to identify and
characterize the cellular receptor for type I FCoV. This
would allow for the development of cell lines that
efficiently replicate and propagate type I FCoV, which, in
turn, would facilitate the investigation of these more
clinically relevant viruses and aid in the development of a
type I FCoV reverse genetics system.
METHODS
Cell lines and antibodies. Cultured cell lines were maintained in
Dulbecco’s modified Eagle’s medium with 10–15% fetal bovine
serum (FBS), 100 U penicillin G sulphate ml
21, 100 mg streptomycin
sulphate ml
21 and non-essential amino acids. For routine growth, cell
monolayers in 75 cm
2 tissue culture flasks were kept at 37uCi n5%
CO2 humidified incubators. All cell lines were adherent and were
passaged when confluent. CrFK, Fcwf-4, swine testicular (ST) and
human embryonic kidney (HEK 293T) cells were purchased from the
ATCC. Feline kidney Colorado University (FKCU) cells were a gift
from T. Gruffydd-Jones (Division of Companion Animal Studies,
University of Bristol, Langford House, Langford, BS40 5DU, UK).
The FCoV type II S glycoprotein-specific mAb 23F4.4 (Corapi et al.,
1992) was a gift from P. Rottier (Virology Division, Department of
Infectious Diseases and Immunology, Yalelaan 1, 3584 CL Utrecht,
The Netherlands). The FCoV type I hyperimmune polyclonal serum
210-70-FIP1 was purchased from VMRD. AlexaFluor-488 goat anti-
mouse IgG and fluorescein isothiocyanate (FITC)-conjugated goat
anti-cat IgG were purchased from Invitrogen and Jackson Im-
munoResearch, respectively. Alkaline phosphatase (AP)-conjugated
goat anti-cat IgG was also purchased from Jackson ImmunoResearch.
Isolation of viral RNA. The type II laboratory strain, FIPV 79-1146
(P100), was purchased from ATCC and virus stocks were prepared by
infectingsubconfluentCrFKcellmonolayersatahighm.o.i.Cellculture
supernatant containing virus was harvested at 8 h post-infection,
centrifuged at 800 g for 5 min and stored at 280uC. RNA was isolated
from the cell culture supernatant using a QIAamp viral RNA mini kit
(Qiagen) according to the manufacturer’s instructions and the eluted
RNA was stored at 280uC. Type I FCoV RNA was extracted at post-
mortem from the jejunum of a cat with a histopathologically confirmed
diagnosis of FIP. A 0.5 cm
3 cube of jejunum was placed into 2 ml
RNAlater solution (Qiagen) and stored at 4uCo v e r n i g h t .T h eR N A l a t e r
solution was then discarded and the tissue stored at 280uC. RNA was
isolated from the tissue biopsy using a Macherey-Nagel Nucleospin
RNA II extraction kit (Macherey-Nagel) according to the manufac-
turer’s instructions. RNA was stored at 280uC.
Amplification of viral RNA. Primers for PCR amplification of the
FCoV S genes were designed using the Lasergene-6 Primer Design
software (DNASTAR). In order to facilitate cloning of PCR products
into the pCAGGS expression vector (Niwa et al., 1991), the forward
and reverse primers were designed to incorporate KpnI and XhoI
restriction sites, respectively. The forward primers were also designed
with a preferred Kozak sequence (GCCACCAUG) (Kozak, 1987)
incorporating the S gene start codon (see Supplementary Table S1,
available in JGV Online). The FCoV S genes were amplified using a
Superscript One-Step RT-PCR for Long Templates kit (Invitrogen)
according to the manufacturer’s instructions. Briefly, a 50 ml reaction
containing RNA, 15 pmol forward primer, 15 pmol reverse primer,
1 ml Superscript II RT/Platinum Taq HiFi DNA polymerase enzyme
mix and 16 reaction buffer was incubated at 50uC for 30 min and
94uC for 2 min, followed by 35 cycles of 94uC for 15 s, 55uC for 30 s
and 68uC for 4.75 min. The reaction was held at 72uC for 7 min and
then stored at 4uC. Primer removal was done using a Qiagen PCR
Purification kit according to the manufacturer’s instructions.
Recombinant DNA and sequencing. Recombinant DNA proce-
dures, including gel electrophoresis, restriction enzyme digestion,
modification and ligation of DNA, transformation of chemically
competent cells and plasmid DNA isolation followed standard
procedures (Ausubel et al., 1987) or were done according to the
manufacturer’s instructions. PCR products were cloned into pCR-
Blunt II-TOPO vector DNA (Invitrogen) and DNA fragments were
extracted from agarose gel using a Qiagen gel purification kit.
Thermal cycle sequencing of PCR products and plasmid DNA was
done with ABI v3.1 BIG DYE mix (Applied Biosystems) and,
following primer removal, the reaction products were analysed with
an ABI 310 Genetic Analyzer. Sequencing primers were designed from
the FIPV 79-1146 and the FCoV C1Je S glycoprotein gene sequences;
GenBank accession nos DQ010921 and DQ848678 (Dye & Siddell,
2005), and published vector sequences (see Supplementary Table S1,
available in JGV Online). Computer-assisted analysis of sequence data
was done using the Lasergene-6 Seqman software (DNASTAR).
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cells were grown to 50–80% confluency in six-well culture plates or
six-well culture plates containing glass coverslips. Fugene-6 transfec-
tion reagent (Roche) was diluted (3:100) in OptiMEM (Invitrogen),
mixed and incubated at room temperature for 5 min. Following the
addition of plasmid DNA (1 mg per 100 ml diluted Fugene-6 reagent),
the tube was mixed again and incubated at room temperature for a
further 30 min. The Fugene-6/OptiMEM/DNA mixture (100 ml) was
added to 5610
5 cells in a drop-wise fashion and the plates were
agitated gently to ensure homogeneous mixing. Cells were then
incubated for 48 h at 37uC.
Immunofluorescence for the detection of viral S glycoproteins.
Transfected cells were washed twice with cold PBS and incubated at
room temperature for 15 min with PBS containing 4% methanol-
stabilized formaldehyde. Cells were then washed three times with PBS
and incubated at 4uC for 1 h with saponin buffer (PBS containing
0.1% saponin, 0.1% sodium azide and 10% FBS). The fixed,
permeablized cells were incubated at 4uC for 1 h with primary
antibody (diluted 1:100 in saponin buffer), washed three times with
saponin buffer and then incubated at room temperature for 30 min
with a secondary antibody (diluted 1:10000 in saponin buffer). After
washing three times in saponin buffer, the coverslips were mounted in
Vectasheild mounting medium with 4,6-diamidino-2-phenylindole
(DAPI; Vector) and viewed under a fluorescence microscope.
Fluorescence-activated cell sorting (FACS) analysis for the
detection of cell surface expressed viral S glycoproteins.
Transfected cells were trypsinized, resuspended in medium and
centrifuged at 400 g for 5 min at room temperature. The cell pellet
was washed twice in staining buffer (PBS containing 0.1% sodium
azide and 2% FBS) and the cells were resuspended in primary
antibody (diluted 1:100 in staining buffer) at 8610
6 cells ml
21. After
a 30 min incubation at 4uC, the cells were washed with staining
buffer and resuspended in secondary antibody (diluted 1:10000 in
staining buffer) at 8610
6 cells ml
21. Cells were incubated in the dark
at 4uC for 20 min and then washed with staining buffer. Cells were
resuspended in staining buffer at 8610
5 cells ml
21 and propidium
iodide (PI) viability stain was added to a concentration of
50 mgm l
21. Cell suspensions were placed on ice in the dark and
analysed by flow cytometry using the FACScan system. Non-viable PI-
positive cells were excluded based on light scatter and the remaining
gated cells were analysed for fluorescence. Data were acquired and
analysed using the Cell Quest software (BD Biosciences).
Production of viral pseudotypes. Retroviral pseudotypes were
produced using the three plasmid, transient transfection method in
which HEK 293T cells were co-transfected with three plasmids
expressing the murine leukemia virus (MLV) gag/pol genes (pCMVi),
the FCoV S glycoprotein (this paper) or vesicular stomatitis virus-G
protein genes (pMDG) and an enhanced GFP reporter construct
(pCNCG), respectively (Naldini et al., 1996; Towers et al., 2000).
Briefly, HEK 293T cells were grown to 80% confluency in 25 cm
2
dishes. A mixture of the three plasmid DNA constructs (see
Supplementary Table S2, available in JGV Online) was prepared and
added to a Fugene-6/OptiMEM mixture. The Fugene-6/OptiMEM/
DNA mixture was incubated at room temperature and was added to
the cells in a drop-wise fashion. Plates were agitated gently to ensure
homogeneous mixing and the cells were then incubated at 37uCi n5%
CO2. Supernatant was harvested 48 and 72 h post-transfection, filtered
through 0.45 mm filters and stored at 280uC.
Transduction of cultured cell lines with viral pseudotypes. Cell
culture supernatant containing viral pseudotypes was supplemented
with 160 mg Polybrene (Chemicon) ml
21 and added to subconfluent
(50–80%) cell monolayers [50 ml (ml cell culture medium)
21] in a
drop-wise fashion. Plates were agitated gently to ensure homogeneous
mixing and the cells were incubated for 72 h at 37uCi n5%C O 2. The
expression of GFP was monitored at 520 nm with a Nikon Eclipse
TS100 microscope.
ELISA for the detection of S glycoprotein on viral pseudotypes.
ELISA microtitre plates were coated overnight at 4uC with cell culture
supernatant containing retroviral pseudotypes diluted in coating
buffer (100 mM Na2CO3, 100 mM NaHCO3, pH 9.6). Plates were
washed with PBS containing 0.1% Tween 20 and residual protein
binding was blocked with blocking solution (PBS containing 0.1%
Tween 20, 1% BSA) for 1 h at 21uC. Duplicate twofold dilutions of
primary antibody in blocking solution (1:10–1:2560) were added to
antigen-coated and uncoated wells at 21uC for 1.5 h. Plates were
washed three times with PBS containing 0.1% Tween 20 and AP-
conjugated secondary antibody diluted 1:10000 in PBS containing
0.05% Tween 20 was added. After 1 h at 21uC, plates were washed
three times with PBS containing 0.1% Tween 20. ELISAs were
developed with Sigma Fast pNPP tablets (1.0 mg pNPP ml
21, 0.2 M
Tris/HCl, pH 8.0 buffer). Following a 1 h incubation at 37uC, plates
were read at 405 nm.
Transduction of feline adherent polymorphonuclear cell cul-
tures with viral pseudotypes. Heparinized whole blood was taken
from specific-pathogen-free cats and 15 ml aliquots were mixed with
an equal volume of RPMI 1640 medium and layered on to 10 ml
Ficoll-Paque PLUS (GE Healthcare). After centrifugation for 40 min
at 400 g, the upper serum layer was removed, the polymorphonuclear
cell layer was harvested and then washed four times in RPMI 1640
medium. Cells were counted and taken up in RPMI 1640 medium
containing 10% FBS, 1000 U penicillin ml
21 and 1000 mg strepto-
mycin ml
21 to give a cell concentration of 2610
6 cells ml
21. Aliquots
of 250 ml were added to wells of a 24-well culture plate. After 24 h, the
medium was removed and replaced with 0.5 ml fresh medium. This
process was repeated daily for 3 days and then twice weekly.
Cell culture supernatant containing viral pseudotypes was supple-
mented with 160 mg Polybrene (Chemicon) ml
21 and added [50 ml
(ml cell culture medium)
21] in a drop-wise fashion to adherent feline
polymorphonuclear cell cultures that had been maintained for 7–
14 days. Plates were agitated gently to ensure homogeneous mixing
and the cells were incubated for 72 h at 37uCi n5 %C O 2. The
expression of GFP was monitored at 520 nm with a Nikon Eclipse
TS100 microscope.
RESULTS
Amplification and cloning of the FCoV types I and
II S genes
RNA was isolated from FIPV 79-1146-infected cell culture
supernatant and from the jejunum of a cat with FIP. The
type II and type I FCoV S genes were amplified respectively
in one-step RT-PCR reactions. Primer sets T003/T004 and
T013/T014 were used to produce truncated cDNA versions
of the type II (4347 bp) and type I (4392 bp) S genes. The
truncated versions of the S glycoprotein genes terminated
11 codons upstream of the authentic S gene stop codon
and eliminated a dibasic retention signal (KXHXX, KVHV/
IH), which is proposed to contribute to the localization of
FCoV S glycoprotein to the site of virus assembly at the
endoplasmic reticulum–Golgi intermediate compartment
(Lontok et al., 2004). Primer sets T009/T010 and T013/
T015 were used to produce full-length versions of the type
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S gene PCR cDNA fragments was then cloned into the
Blunt II-TOPO vector and colonies containing the correct
plasmid inserts were identified by restriction enzyme
analysis. Sequencing the S gene cDNA inserts was done
using FCoV type II and type I S gene-specific primers and
the Blunt II-TOPO vector-specific primers M13-F and
M13-R. This revealed the presence of mutations in each
construct. Before proceeding, these mutations were
repaired by the exchange of restriction fragments from
cDNA clones with authentic S glycoprotein gene sequences.
Because of the position of the mutations and a lack of
convenient restriction sites in the type I S gene constructs,
silent mutations at positions 474 (AAG) and 1827 (TAC)
were not repaired. Plasmid DNA from the four Blunt II-
TOPO S gene constructs was digested using KpnI and XhoI
and the S gene fragments were ligated into the multiple
cloning site of pCAGGS vector DNA. The correct plasmid
inserts were identified by restriction enzyme analysis, and
nucleotide sequencing confirmed that all four inserts had
the expected S gene nucleotide sequence. The vector–
cDNA junctions were also verified by sequencing with
vector-specific primers, pCAGG-F and pCAGG-R (see
Supplementary Table S1, available in JGV Online). The
constructs were designated pCAGGS/FCoVII-Str (type II,
truncated), pCAGGS/FCoVII-S (type II, full-length),
pCAGGS/FCoVI-Str (type I, truncated) and pCAGGS/
FCoVI-S (type I, full-length).
Intracellular FCoV S gene expression using
immunofluorescence assay (IFA)
IFA was used to confirm FCoV S gene expression following
the transfection of HEK 239T cells with the pCAGGS
expression plasmids. HEK 293T cells grown to 80%
confluency on coverslips were transfected with pCAGGS/
FCoVII-Str, pCAGGS/FCoVII-S, pCAGGS/FCoVI-Str and
pCAGGS/FCoVI-S plasmid DNA, or with pCAGGS/Ta1
plasmid DNA (N. Temperton, unpublished) as a negative
control. IFA was done 48 h post-transfection using the
23F4.4 mAb or the 210-70-FIP1 polyclonal serum as the
primary antibody and AlexaFluor-488 goat anti-mouse
IgG or FITC-conjugated goat anti-cat IgG as the
secondary antibody. When viewed under the fluorescence
Fig. 1. Intracellular and cell surface expression of FCoV surface glycoproteins. (a) HEK 293T cells grown on coverslips were
transfected with (i) pCAGGS/FCoVII-Str, (ii) pCAGGS/FCoVII-S, (iii) pCAGGS/FCoVI-Str, (iv) pCAGGS/FCoVI-S or (v)
pCAGGS/Ta1 plasmid DNA. Cells were permeabilized and stained 48 h post-transfection using 23F4.4 mAb [(i), (ii) and (v)] or
210-70-FIP1 polyclonal serum [(iii) and (iv)] as the primary antibody and AlexaFluor-488 goat anti-mouse IgG [(i), (ii) and (v)] or
FITC-conjugated goat anti-cat IgG [(iii) and (iv)] as the secondary antibody. Stained cells were viewed using a fluorescence
microscope. (b) HEK 293T cells were transfected with (i) pCAGGS/FCoVII-Str, (ii) pCAGGS/FCoVII-S, (iii) pCAGGS/FCoVI-
Str or (iv) pCAGGS/FCoVI-S, or plasmid DNA. Cells were trypsinized and stained 48 h post-transfection using the 23F4.4
mAb [(i) and (ii)] or the 210-70-FIP1 polyclonal serum [(iii) and (iv)] as the primary antibody and AlexaFluor-488 goat anti-mouse
IgG [(i) and (ii)] or FITC-conjugated goat anti-cat IgG [(iii) and (iv)] as the secondary antibody. Cells were analysed for
fluorescence by flow cytometry using the FACScan system.
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approximately 30–40% of the pCAGGS/FCoVII-Str and
pCAGGS/FCoVII-S transfected cells, and approximately
20–25% of the pCAGGS/FCoVI-Str and pCAGGS/FCoVI-
S transfected cells. No fluorescence was evident in the
pCAGGS/Ta1 transfected negative-control cells (Fig. 1a).
Cell surface FCoV S gene expression
During the formation of retroviral pseudotypes, the surface
protein from a heterologous virus is likely to be incor-
porated into the viral particle, predominantly during
budding of the virus from the cell surface. For surface
proteins to be effectively incorporated into the viral
pseudotype, it is therefore preferable that they are
expressed at the host cell membrane. HEK 293T cells
were transfected with pCAGGS/FCoVII-Str, pCAGGS/
FCoVII-S, pCAGGS/FCoVI-Str and pCAGGS/FCoVI-S
plasmid DNA, and FACS analysis was used to quantify
surface expression of the FCoV S glycoproteins 48 h post-
transfection. The results show that the highest levels of
S glycoprotein surface expression were obtained in the
cells transfected with the truncated S gene constructs.
Approximately, 41% of cells transfected with the truncated
type II S gene plasmid (pCAGGS/FCoVII-Str) were fluores-
cence positive, in contrast to only 2% of cells transfected
with the full-length type II S gene plasmid (pCAGGS/
FCoVII-S). Similarly, 11% of cells transfected with the
truncated type I S gene plasmid (pCAGGS/FCoVI-Str)
were fluorescence positive, in contrast to only 3% of cells
transfected with the full-length version (pCAGGS/FCoVI-
S) (Fig. 1b). These results demonstrate that truncated
forms of the FCoV S glycoprotein should be used to
produce high titre viral pseudotypes and they support the
idea that the dibasic motif identified at the carboxyl
terminus of the FCoV S glycoprotein (Lontok et al., 2004)
is indeed an intracellular retention signal.
Cellular tropism of viral pseudotypes
Four MLV-based viral pseudotypes were produced: pseu-
dotypes containing the truncated forms of either the FCoV
type I or type II S glycoproteins [MLV(FCoVI-Str) and
MLV(FCoVII-Str)], pseudotype containing the VSV-G
surface protein [MLV(VSV-G), positive control] and
psuedotype with no surface protein, which we refer to as
‘bald’ pseudotype [MLV(bald)]. Three established feline
continuous cell lines (CrFK, Fcwf-4 and FKCU), ST and
HEK 293T cells were grown to 80% confluency and
incubated with each of the viral pseudotypes. At 72 h post-
transduction, the cells were monitored for GFP expression.
In all cell lines, GFP expression could be detected in cells
transduced with the MLV(VSV-G) viral pseudotype. Also
as expected, no GFP expression could be detected in cells
Fig. 2. Cellular tropism of viral pseudotypes.
CrFK (a, b, c and d), Fcwf-4 (e, f, g and h),
FCKU (i, j, k and l), HEK 293T (m, n, o and p)
and ST (q, r, s and t) cells were incubated with
MLV(VSV-G) (a, e, i m and q), MLV(bald) (b, f,
j, n and r), MLV(FCoVII-Str) (c, g, k, o and s) or
MLV(FCoVI-Str) (d, h, l, p and t) viral
pseudotypes. At 72 h post-incubation, the
cells were analysed for GFP expression at
520 nm using a 10 (a to h) or 40 (i to t)
objective on a Nikon Eclipse TS100 fluores-
cence microscope.
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S pseudotype, MLV(FCoVII-Str), was able to transduce
GFP expression in CrFK, Fcwf-4 and FKCU cells but not
in ST or HEK 293T cells. And finally, there was no evidence
of GFP expression in any of the cell lines that had
been incubated with the FCoV type I S pseudotype,
MLV(FCoVI-Str) (Fig. 2).
These results suggest to us that the feline cell lines tested
did not express a receptor for the type I FCoV S glyco-
protein. In contrast, they were clearly transduced with
pseudotypes bearing the FCoV type II S glycoprotein,
which is known to use fAPN as a receptor for attachment
and entry. However, as the levels of S glycoprotein
expression in HEK 239T cells transfected with both type
I and type II truncated S glycoprotein constructs were not
the same (Fig. 1), it is possible that, compared with the
FCoV type II pseudotypes, the FCoV type I pseudotypes
had failed to incorporate a sufficient density of membrane-
bound S glycoprotein. To address this, two further experi-
ments were done. First, an ELISA assay was done to detect
the presence of the FCoV type I S glycoprotein in the FCoV
type I pseudotype particles. ELISA plates were coated with
the MLV(FCoVI-Str) pseudotype supernatant diluted in
coating buffer and the 210-70-FIP1 antiserum was used as
the primary antibody. The results are shown in Fig. 3. The
two control samples (coating buffer only and coating with
medium) were negative over the range of dilutions tested. In
contrast, at two different antigen concentrations, the FCoV
type I pseudotype supernatant showed a positive signal
relative to the primary antibody concentration. These results
indicate that type I S glycoprotein is present within the
FCoV type I pseudotype supernatant, and most likely
associated with retroviral cores.
Second, and more importantly, the retroviral pseudotypes
were used to transduce cultures of adherent polymorpho-
nuclear cells that had been obtained from the blood of
specific-pathogen-free cats. These primary cell cultures
were cultivated without growth factors (e.g. interleukin-4
and granulocyte–macrophage colony-stimulating factor)
and were mainly of monocyte morphology. The results are
shown in Fig. 4. In these cultures, GFP expression was
detected in cells transduced with the MLV(VSV-G) viral
pseudotype and, as expected, no GFP expression could be
detected in cells incubated with MLV(bald) pseudotypes.
Both the FCoV type I S pseudotype, MLV(FCoVI-Str)
and the FCoV type II S pseudotype, MLV(FCoVII-Str),
were able to transduce GFP expression in a significant
Fig. 3. ELISA of FCoV type I S glycoprotein in MLV(FCoVI-Str)
retroviral pseudotypes. ELISA microtitre plates were coated with
cell culture supernatant containing a 1:32 dilution MLV(FCoVI-
Str) retroviral pseudotypes diluted in coating buffer (&), a 1:64
dilution MLV(FCoVI-Str) retroviral pseudotypes diluted in coating
buffer (h), cell culture supernatant diluted in coating buffer ($)o r
coating buffer alone (#). Duplicate twofold dilutions of primary
antibody (1:10–1:2560) were incubated with antigen-coated
and uncoated wells and bound antibody was detected with AP-
conjugated secondary antibody and pNPP. Plates were read at
405 nm. Fig. 4. Transduction of feline adherent polymorphonuclear cells
with MLV(FCoVI-Str) retroviral pseudotypes. Feline adherent
polymorphonuclear cell cultures were incubated with MLV(VSV-
G) (a and b), MLV(bald) (c and d), MLV(FCoVI-Str) (e and f) or
MLV(FCoVII-Str) (g and h) viral pseudotypes. At 72 h post-
incubation, the cells were visualized by microscopy (a, c, e and g)
and analysed for GFP expression at 520 nm (b, d, f and h) using a
Nikon Eclipse TS100 fluorescence microscope.
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pseudotypes had sufficient FCoV type I S glycoprotein
incorporated in their envelope membrane to mediate
transduction of primary feline, most probably monocyte,
cells.
DISCUSSION
The main conclusion of the experiments reported here is
that fAPN does not function as a receptor for the
attachment and entry of FCoV type I viruses. This is based
upon the inability of retroviral pseudotypes bearing the
FCoV type I S glycoprotein to transduce cells that express
fAPN and can be transduced by retroviral pseudotypes
bearing the FCoV type II S glycoprotein. This conclusion is
consistent with the difficulties encountered in the isolation
and propagation of type I FCoV in feline cell culture and is
in agreement with the conclusions of Hohdatsu et al.
(1992). However, it is not consistent with the report by
Tresnan et al. (1996) that the UCD-1 strain of FIPV, a type
I virus, is able to infect and express viral antigens in
hamster and mouse cells that had been stably transfected
with fAPN cDNA. It is, perhaps, relevant to note that in
the experiments reported by Tresnan et al. (1996), the
infection of fAPN-transfected hamster cells was much
lower with type I viruses, compared with type II viruses (2
and 30% of cells in tranfected cultures, respectively). At
the moment, we can only suggest that the expression of
fAPN in mouse or hamster cells, or the selection of cells in
G418 is able to augment the infection of a small percentage
of cells by a fAPN-independent route.
Also, in apparent contradiction to our results, there are
several reports stating that type I FCoV can infect Fcwf-4
cells (Hohdatsu et al., 1998; Jacobse-Geels & Horzinek,
1983), a cell line that we were unable to transduce with
FCoV type I pseudotypes. It is noteworthy, however, that
in these studies, the type I viruses used showed only a low
level of cell-associated infection and that attachment or
adsorption of virus to these cells could be significantly
enhanced by low-speed centrifugation or the inclusion of
polymeric cations, such as DEAE-dextran in the culture
medium during the absorption period (Hohdatsu et al.,
1995). Our interpretation is that the FCoV type I S
glycoprotein–receptor interaction at the surface of Fcwf-4
cells is of low affinity and is not sufficient to mediate a
level of pseudotype transduction that is detectable in our
system. Also, it is possible that in the absence of a high
affinity receptor-mediated entry mechanism, the phago-
cytic activity of the macrophage-like Fcfw-4 cell line
rapidly depletes the culture supernatant of retroviral
pseudotypes.
The results of this study also suggest that the viral
pseudotypes reported here may be useful for the identifica-
tion of the cellular receptor for type I FCoV and the
development of cell lines that would efficiently replicate
and propagate type I FCoV. In the first instance, the viral
pseudotypes could be used to screen for continuous feline
cell lines that are permissive for attachment and entry.
However, type I FCoV appears to have an extremely
narrow host range and cell tropism, and we consider it
probable that even if such a cell line was found, it would be
unlikely to be useful for non-cell-associated virus replica-
tion. The most promising candidate would probably be
feline gut epithelial cell line because FCoV is primarily an
enteric virus that binds to the apical surface of gut
epithelial cells in the feline gastrointestinal tract (Rossen
et al., 2001). Unfortunately, there are no feline gut cell lines
available commercially. An alternative strategy would be to
identify the FCoV type I virus receptor and to produce a
permissive cell line that expresses this receptor at its cell
surface. Again, the viral pseudotypes could be used to
identify cells, for example in gut explant or peripheral
blood monocyte cell cultures, that express the type I FCoV
receptor and then to use these cells as a source of receptor
protein-enriched membranes or receptor mRNA-enriched
RNA. From this point onwards, the identification of the
FCoV receptor, the production of a FCoV receptor cDNA
and the generation of a stably transfected, receptor-
expressing feline cell line could follow strategies that have
proven successful for other viruses (Assavalapsakul et al.,
2006; Tatsuo et al., 2000). Such a cell line would be a
valuable tool for future FCoV studies.
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